Nintedanib Sandoz

Nintedanib, the active ingredient in Nintedanib Sandoz, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is used to treat idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain types of non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for clinical and commercial programs.

Nintedanib is indicated for fibrotic lung disorders and selected oncologic indications, acting on pathways that drive fibrosis and tumor angiogenesis.

- Idiopathic pulmonary fibrosis: slows disease progression, reduces decline in forced vital capacity and improves survival outcomes. - Systemic sclerosis‑associated interstitial lung disease: limits lung function deterioration and may improve forced vital capacity in affected adults. - Non‑small cell lung cancer (selected patients): inhibits tumor angiogenesis and proliferation, contributing to disease control when used according to oncologic guidelines.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, often manageable with diet. - Vomiting: occasional episodes, usually early in therapy. - Decreased appetite: reduced food intake leading to weight loss. - Abdominal pain: discomfort in the stomach region. - Liver enzyme elevation: mild increases in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Bleeding events: gastrointestinal or intracranial hemorrhage, especially with anticoagulants. - Cardiovascular events: myocardial infarction, arterial thrombosis, or hypertension. - Severe infections: opportunistic infections in immunocompromised patients. - Pulmonary embolism: rare clot formation in pulmonary arteries.

Before initiating therapy, clinicians should assess baseline organ function and comorbid conditions.

- Liver function monitoring: perform baseline and periodic liver enzyme tests. - Bleeding risk assessment: evaluate for anticoagulant use or history of hemorrhage. - Cardiovascular evaluation: monitor blood pressure and signs of ischemic events. - Dose adjustment in hepatic impairment: reduce dose or avoid in severe impairment. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at below 25°C: keep in the original pack, protect from moisture and light.

Nintedanib may interact with drugs that affect its metabolism or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increase bleeding potential. - Antiplatelet agents (e.g., aspirin, clopidogrel): heighten hemorrhage risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - P‑gp inhibitors (e.g., verapamil): modestly increase exposure. - Diuretics: may affect fluid balance and renal function.